

Publikacije

1. van Exel NJA, Bobinac A, Koopmanschap MA, Brouwer WBF (2007) Providing informal care: a burden and a blessing. Geneva Association Information Newsletter: Health and Ageing 16: 10-13.
2. NJA van Exel, A Bobinac, MA Koopmanschap, WBF Brouwer. (2008) The invisible hands made visible: recognizing the value of informal care in healthcare decision-making. Expert Review of Pharmacoeconomics and Outcomes Research, 8: 557-56
3. Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF (2010) Willingness to pay for a Quality-adjusted life-year: the individual perspective. Value in Health 13: 1046-1055.
4. Bobinac A, Van Exel NJA, Rutten FFH, Brouwer WBF (2010) Caring for and caring about: Disentangling the family effect and the caregiving effect. Journal of Health Economics 29: 549-556.
5. Bobinac A, Van Exel NJA, Rutten FFH, Brouwer WBF (2011) Health effects in significant others: Separating family and care giving effects. Medical Decision Making 31: 292-298.
6. Bobinac A, Brouwer WBF, Van Exel NJA (2011) Discounting future health gains: an empirical enquiry into the influence of growing life expectancy. Health Economics 20: 111-119.
7. Bobinac A (2012) Economic evaluations of health technologies: insights into the valuation and measurement of benefits. PhD thesis <http://repub.eur.nl/res/pub/32245/Ana%20thesis.pdf>
8. Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF (2012) Get more, pay more? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation. Journal of Health Economics 31: 158-168.
9. Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF (2012) Inquiry into the relationship between equity weights and the value of the QALY. Value in Health 15: 1119–1126.
10. Bobinac, A. (2013) "Dutch individuals place high monetary value on QALY." Pharmacoeconomics & Outcomes News 693: 5-14.
11. Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF (2013) Valuing QALY gains by applying a societal perspective. Health Economics, 22: 1272-1281.
12. Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF (2014) The value of a QALY: Individual willingness to pay for health gains under risk, Pharmacoeconomics 32:75-86.
13. Bobinac A (2014) "Izazovi i ograničenja u ekonomskoj evaluaciji zdravstvenih tehnologija", u: M. Vehovec (ur.) "O zdravstvu iz ekonomske perspektive", Zagreb: Ekonomski institut Zagreb, str. 301-332.
14. Groenewoud, AS, Van Exel, NJA., Bobinac, A., Berg, M., Huijsman, R., Stolk, EA (2015) What influences patients' decisions when choosing a health care provider? Measuring preferences of patients with knee arthrosis, chronic depression or Alzheimer's disease, using discrete choice experiments. Health Services Research, 50 (6), 1941-1972.
15. van de Wetering, L., van Exel, J., Bobinac, A., Brouwer, W. B. (2015). Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment. Pharmacoeconomics, 1-12.
16. Bobinac, A., & Vehovec, M. (2016). Economic Evaluations of Personalized Health Technologies: An Overview of Emerging Issues. In Personalized Medicine (pp. 107-135). Springer International Publishing.

17. Soeteman, L., van Exel, J., & Bobinac, A. (2016). The impact of the design of payment scales on the willingness to pay for health gains. *The European Journal of Health Economics*, 1-18.
18. Bobinac, A. (2017). Pristup zdravstvenim uslugama u Hrvatskoj. Policy report. https://www.cms.hr/system/publication/pdf/95/Pristup_zdravstvenim_uslugama_u_Hrvatskoj_.pdf
19. Bobinac, A (2019). Mitigating hypothetical bias in willingness-to-pay studies: post-estimation uncertainty and anchoring on irrelevant information. *The European Journal of Health Economics*, 20(1),75-82.
20. Vrdoljak, E., Sekerija, M, Pleastina, S, Belac Lovasic I, Katalinic V, Garattini L, Bobinac A, Voncina L. (2020) IS IT TOO EXPENSIVE TO FIGHT CANCER? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer. *The European Journal of Health Economics*, under review.

Projekti

ZNANSTVENI PROJEKTI (VODITELJ)

1. "Value in health: empirical exploration and application", Uspostavni projekt (UIP-2019-04-3721) **Hrvatska zaklada za znanost** (2020-2025, €178,000)
2. "Hrana I zajednica", **Europski socijalni fond** (ESF) (2018-2019, €170,000)
3. "Where to draw the line?", individualni VENI grant (451-13-006) **Nizozemska organizacija za znanost** (NWO) (2013-2016, €270,000)
4. „When is it too expensive?“ **Nizozemska zaklada za istraživanja i razvoj u zdravstvu** (ZoNMW) (2011-2013, €250,000)
5. "The value of health in cost-effectiveness studies", sa prof. Werner Brouwer i prof. Job van Exel, **konzorcij farmaceutskih tvrtki** (2007-2011, €250,000)

IZABRANI KOMERCIJALNI PROJEKTI

1. **Sveučilište u Zagrebu, Farmaceutsko-biokemijski fakultet (2020)**: Ekonomska evaluacija troškovne-učinkovitosti inovativne ljekarničke usluge u primarnoj zdravstvenoj zaštiti.
2. **Svjetska Banka (2020)**: Članica misije Svjetske banke u Hrvatskoj s ciljem analize politika i financiranja lijekova (naručitelj Ministarstvo financija)
3. **Farmaceutske tvrtke (nazivi klijenata povjerljivi, 2016-2020)**: Izrada studija utjecaja na proračun i analiza troškovne-učinkovitosti lijekova, medicinskih pomagala i javnozdravstvenih intervencija
4. **Ministarstvo poljoprivrede** (2019): Studija izvodljivosti osnivanja banke hrane u Hrvatskoj.
5. **Javno tijelo (naziv klijenta povjerljiv, 2019)**: Ekonomska evaluacija Nacionalnog plana borbe protiv bolesti x.
6. **Svjetska Banka (2018)**: Članica misije Svjetske banke u Hrvatskoj s ciljem analize kvalitete i razine pristupa zdravstvenoj skrbi u Hrvatskoj (naručitelj Ministarstvo zdravstva)